| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | GNRH1 |
| Uniprot No | P01148 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-92aa |
| 氨基酸序列 | MKPIQKLLAGLILLTWCVEGCSSQHWSYGLRPGGKRDAENLIDSFQEIVK EVGQLAETQRFECTTHQPRSPLRDLKGALESLIEEETGQKKI |
| 预测分子量 | 36 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于GNRH1重组蛋白的虚构参考文献示例(仅供格式参考)：
1. **《重组GNRH1蛋白在大肠杆菌中的高效表达与生物活性分析》**
- 作者：Smith J, et al.
- 摘要：研究通过大肠杆菌表达系统生产GNRH1重组蛋白，优化了诱导条件与纯化工艺，并通过体外细胞实验证实其能够激活垂体细胞GnRH受体，促黄体生成素(LH)分泌。
2. **《CHO细胞表达系统生产的GNRH1重组蛋白在生殖调控中的应用》**
- 作者：Zhang L, et al.
- 摘要：利用CHO细胞表达并纯化GNRH1重组蛋白，对比哺乳动物与原核表达系统的产物活性，发现CHO来源的蛋白具有更稳定的翻译后修饰及长效垂体刺激效应。
3. **《GNRH1重组蛋白-药物偶联物靶向治疗前列腺癌的临床前研究》**
- 作者：Johnson R, et al.
- 摘要：将GNRH1重组蛋白与化疗药物偶联，验证其对前列腺癌细胞的靶向杀伤作用，显示其通过特异性结合GnRH受体减少系统毒性并提高疗效。
4. **《GNRH1重组蛋白的晶体结构解析及其受体相互作用机制》**
- 作者：Brown K, et al.
- 摘要：通过X射线晶体学解析GNRH1重组蛋白的三维结构，揭示其与GnRH受体结合的活性位点，为设计新型类似物提供结构基础。
注：以上文献及作者为虚构，实际引用需检索PubMed、Web of Science等数据库获取真实研究。
Gonadotropin-releasing hormone 1 (GNRH1), also known as luteinizing hormone-releasing hormone (LHRH), is a critical neuropeptide regulating reproductive functions. Produced in the hypothalamus, it binds to pituitary receptors to stimulate secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which control gonadal steroidogenesis and gametogenesis. Native GNRH1 is a decapeptide (10-amino-acid chain) derived from a 92-amino-acid precursor protein through enzymatic cleavage. Its short half-life (<5 minutes) and pulsatile secretion pattern limit therapeutic applications of the natural hormone.
Recombinant GNRH1 protein is engineered using genetic modification techniques, typically expressed in bacterial (e.g., E. coli) or mammalian cell systems. The recombinant form preserves the native structure while enabling scalable production with improved batch consistency. Researchers often modify the peptide sequence or conjugate it with stabilizing molecules to prolong its half-life for clinical use. Its applications span therapeutic, veterinary, and research fields. In medicine, recombinant GNRH1 analogs are used to treat infertility, prostate cancer, endometriosis, and central precocious puberty by either stimulating or suppressing gonadotropin release depending on administration protocols. In livestock management, it regulates reproductive cycles and artificial insemination timing. As a research tool, it helps study hypothalamic-pituitary-gonadal axis dynamics, hormone receptor interactions, and reproductive disorder mechanisms.
Commercial production involves codon optimization for host cells, removal of the native signal peptide, and purification via chromatography. Challenges include maintaining conformational stability and bioactivity during manufacturing. Current studies focus on developing sustained-release formulations and targeted delivery systems to enhance clinical efficacy.
×
